GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chengdu Olymvax Biopharmaceuticals Inc (SHSE:688319) » Definitions » Revenue per Share

Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Revenue per Share : ¥1.45 (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chengdu Olymvax Biopharmaceuticals Revenue per Share?

Chengdu Olymvax Biopharmaceuticals's revenue per share for the three months ended in Dec. 2024 was ¥0.50. Chengdu Olymvax Biopharmaceuticals's revenue per share for the trailing twelve months (TTM) ended in Dec. 2024 was ¥1.45.

During the past 12 months, the average Revenue Per Share Growth Rate of Chengdu Olymvax Biopharmaceuticals was 18.60% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 4.70% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 20.20% per year. During the past 10 years, the average Revenue Per Share Growth Rate was 127.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Chengdu Olymvax Biopharmaceuticals's Revenue per Share or its related term are showing as below:

SHSE:688319' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.7   Med: 90.35   Max: 691.6
Current: 4.7

During the past 12 years, Chengdu Olymvax Biopharmaceuticals's highest 3-Year average Revenue Per Share Growth Rate was 691.60% per year. The lowest was 4.70% per year. And the median was 90.35% per year.

SHSE:688319's 3-Year Revenue Growth Rate is ranked better than
64.33% of 771 companies
in the Biotechnology industry
Industry Median: 2.6 vs SHSE:688319: 4.70

Chengdu Olymvax Biopharmaceuticals Revenue per Share Historical Data

The historical data trend for Chengdu Olymvax Biopharmaceuticals's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chengdu Olymvax Biopharmaceuticals Revenue per Share Chart

Chengdu Olymvax Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 1.27 1.35 1.22 1.45

Chengdu Olymvax Biopharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.18 0.38 0.39 0.50

Competitive Comparison of Chengdu Olymvax Biopharmaceuticals's Revenue per Share

For the Biotechnology subindustry, Chengdu Olymvax Biopharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chengdu Olymvax Biopharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chengdu Olymvax Biopharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Chengdu Olymvax Biopharmaceuticals's PS Ratio falls into.


;
;

Chengdu Olymvax Biopharmaceuticals Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Chengdu Olymvax Biopharmaceuticals's Revenue Per Share for the fiscal year that ended in Dec. 2024 is calculated as

Revenue Per Share (A: Dec. 2024 )=Revenue (A: Dec. 2024 )/Shares Outstanding (Diluted Average) (A: Dec. 2024 )
=588.858/405.422
=1.45

Chengdu Olymvax Biopharmaceuticals's Revenue Per Share for the quarter that ended in Dec. 2024 is calculated as

Revenue Per Share (Q: Dec. 2024 )=Revenue (Q: Dec. 2024 )/Shares Outstanding (Diluted Average) (Q: Dec. 2024 )
=202.212/401.715
=0.50

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chengdu Olymvax Biopharmaceuticals  (SHSE:688319) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Chengdu Olymvax Biopharmaceuticals Revenue per Share Related Terms

Thank you for viewing the detailed overview of Chengdu Olymvax Biopharmaceuticals's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Chengdu Olymvax Biopharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
99 Tianxin Road, High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
Executives
Chen Dao Yuan Core technical personnel
Li Hong Guang Core technical personnel
Fan Shao Wen Directors, senior managers
Ma Heng Jun senior management
Wu Wei senior management
Fan Fan Director
Chen Ai Min Director
Tan Yong senior management
Lu Lu Director
Yu Yun Hui Director
Zhang Li Ying Core technical personnel
Chen Ke Ping Core technical personnel
Wu Qiang Core technical personnel
Yang Feng Core technical personnel

Chengdu Olymvax Biopharmaceuticals Headlines

No Headlines